Title:
|
Left ventricular geometry and blood pressure as predictors of adverse progression of fabry cardiomyopathy
|
Author:
|
Krämer, Johannes Harald; Bijnens, Bart; Stork, Stefan; Ritter, Christian Oliver Liver; Liu, Dan; Ertl, George; Wanner, Christoph; Weidemann, Frank
|
Abstract:
|
BACKGROUND/nIn spite of several research studies help to describe the heart in Fabry disease (FD), the cardiomyopathy is not entirely understood. In addition, the impact of blood pressure and alterations in geometry have not been systematically evaluated./n/nMETHODS/nIn 74 FD patients (mean age 36±12 years; 45 females) the extent of myocardial fibrosis and its progression were quantified using cardiac magnetic-resonance-imaging with late enhancement technique (LE). Results were compared to standard echocardiography complemented by 2D-speckle-tracking, 3D-sphericity-index (SI) and standardized blood pressure measurement. At baseline, no patient received enzyme replacement therapy (ERT). After 51±24 months, a follow-up examination was performed./n/nRESULTS/nSystolic blood pressure (SBP) was higher in patients with vs. without LE: 123±17 mmHg vs. 115±13 mmHg; P = 0.04. A positive correlation was found between SI and the amount of LE-positive myocardium (r = 0.51; P<0.001) indicating an association of higher SI in more advanced stages of the cardiomyopathy. SI at baseline was positively associated with the increase of LE-positive myocardium during follow-up. The highest SBP (125±19 mmHg) and also the highest SI (0.32±0.05) was found in the subgroup with a rapidly increasing LE (ie, ≥0.2% per year; n = 16; P = 0.04). Multivariate logistic regression analysis including SI, SBP, EF, left ventricular volumes, wall thickness and NT-proBNP adjusted for age and sex showed SI as the most powerful parameter to detect rapid progression of LE (AUC = 0.785; P<0.05)./n/nCONCLUSIONS/nLV geometry as assessed by the sphericity index is altered in relation to the stage of the Fabry cardiomyopathy. Although patients with FD are not hypertensive, the SBP has a clear impact on the progression of the cardiomyopathy. |
Abstract:
|
This work was supported by grants from the Bundesministerium für Bildung und Forschung (BMFBF01 EO1004). CW and FW are members of the Fabry Registry European Board of Advisors which is sponsored by Genzyme Corporation (Cambridge, MA, USA). JK, MN, FW and CW have received speakers honoraria and FW and CW has received research support (grant to the institution) from Genzyme and Shire Corporation. |
Subject(s):
|
-Cardiomyopathies -Fibrosis -Blood pressure -Myocardium -Echocardiography -Heart -Magnetic resonance imaging -Regression analysis |
Rights:
|
© 2015 Krämer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
http://creativecommons.org/licenses/by/4.0/ |
Document type:
|
Article Article - Published version |
Published by:
|
Public Library of Science (PLoS)
|
Share:
|
|